Life Sciences Tools and Services
Company Overview of AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP operates as a biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines to customers worldwide. It offers a pipeline of medicines primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. The company was founded in 1912 and is headquartered in Wilmington, Delaware with a strategic research and development center in Gaithersburg, Maryland. It also has research and development, manufacturing, and commercial office locations in California, Delaware, Kentucky, Massachusetts, Maryland, North Carolina, Ohio, and Pe...
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
Founded in 1912
Key Executives for AstraZeneca Pharmaceuticals LP
Chief Financial Officer and Vice President of Finance - North America
Executive Vice President of North America and President of Astrazeneca US
President of Astrazeneca Canada Inc
Vice President of Medical Affairs and US Head Medical Officer
Chief Operating Officer of U.S. Business
Compensation as of Fiscal Year 2015.
AstraZeneca Pharmaceuticals LP Key Developments
Cerulean Pharma Inc. Enters into Lease Agreement with Astrazeneca Pharmaceuticals Limited Partnership
Jul 14 15
On July 9, 2015, Cerulean Pharma Inc. (the Company) entered into a lease agreement (the Lease) with AstraZeneca Pharmaceuticals Limited Partnership, a Delaware limited partnership (the Landlord), for approximately 22,992 square feet of laboratory and office space at 35 Gatehouse Drive in Waltham, Massachusetts. The term of the Lease commences on December 28, 2015 and expires on February 28, 2021. During each of the first two years of the term, the Company's annual base rent will be $689,760. The annual base rent shall increase each year thereafter. In addition to the base rent, the Company is also responsible for its share of the operating expenses, utility costs and real estate taxes, in accordance with the terms of the Lease. Pursuant to the terms of the Lease, the Company is required to provide a security deposit in the form of a letter of credit in the amount of $229,920. The Company has the right to extend the term of the Lease for one three-year term, provided that the Company provides notice to the Landlord not later than 12 months prior to the expiration date of the initial term. The base rent for the extension term, if any, will be determined based on market conditions existing at such time in accordance with the terms of the Lease. The Lease contains customary provisions allowing the Landlord to terminate the Lease if the Company fails to remedy a default of any of its obligations under the Lease within specified periods or upon the bankruptcy or insolvency of the Company.
Faruqi & Faruqi, LLP and Berger & Montague,P.C. Reach Whistleblower Lawsuit Settlement with AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc
Jul 7 15
Faruqi & Faruqi, LLP and co-counsel Berger & Montague,P.C. announced that they have reached a settlement in three separate but related whistleblower lawsuits alleging violations of the False Claims Act against AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc., for a total of $55.5 million. The cases were jointly prosecuted by Faruqi & Faruqi, LLP and Berger & Montague, P.C. on behalf of Relator Ronald J. Streck, who filed this action in 2008. Under the terms of the settlement, AstraZeneca will pay $46.5 million, Cephalon will pay $7.5 million, and Biogen will pay $1.5 million. Claims against a fourth drug manufacturer, Genzyme Corporation, are still being litigated. The case, pending in federal court in the Eastern District of Pennsylvania, is captioned United States ex rel. Ronald Streck versus Allergan, et al., Case No. 08-cv-5135. The lawsuit, filed on behalf of the United States under the False Claims Act (FCA) and State False Claims Acts alleges that a number of pharmaceutical manufacturers, including AstraZeneca, Cephalon and Biogen, fraudulently underpaid mandatory rebates to state Medicaid programs. Streck's lead attorney, T. Talyana Bromberg of Faruqi & Faruqi, LLP, stated: "When pharmaceutical companies manipulate prices in order to underpay Medicaid, every taxpayer suffers.
The Third U.S. Circuit Court of Appeals Affirms Dismissal of a Relator's False Claims Act Suit Against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P
Nov 7 14
The Third U.S. Circuit Court of Appeals affirmed the dismissal of a relator's False Claims Act (FCA) suit against pharmaceutical companies, agreeing with a district court that the relator failed to show he was the original source of information about the companies' alleged wrongdoing. Karl Schumann, proceeding as a qui tam relator under the FCA and corresponding state laws, brought an action against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. (collectively, the defendants). Schumann alleged the defendants improperly induced Medco Health Solutions Inc., his employer, to offer certain of the defendants' drugs in its mail-order pharmacies and in health plans it managed; did not include those inducements when calculating the best price for their drugs and thus submitted inaccurate best price reports to the government; overcharged the government based on those inaccurate best prices; and underpaid rebates owed based on those inaccurate best prices. The district court found it lacked subject matter jurisdiction over Schumann's claims because he did not have the requisite direct and independent knowledge to satisfy the original source exception to the FCA's public disclosure bar. As a result, the court dismissed Schumann's claims with prejudice. Schumann appealed. The Third Circuit affirmed the district court's judgment. In so ruling, the Third Circuit found Schumann's knowledge gained through the application of expertise to information publicly disclosed under 31 U.S.C. §3730(e)(4)(A) was not independent, and Schumann failed to aver facts indicating he had direct and independent knowledge of any false or fraudulent claim submitted or caused to be submitted by the defendants. Therefore, Schumann was not an original source of the information underlying his FCA claims against the defendants.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|